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Abstract: Immune checkpoint inhibitors (ICIs) have changed therapeutic algorithms in several
malignancies, although intrinsic and secondary resistance is still an issue. In this context, the dysregulation
of immuno-metabolism plays a leading role both in the tumor microenvironment (TME) and at the
host level. In this review, we summarize the most important immune-metabolic factors and how they
could be exploited therapeutically. At the cellular level, an increased concentration of extracellular
adenosine as well as the depletion of tryptophan and uncontrolled activation of the PI3K/AKT
pathway induces an immune-tolerant TME, reducing the response to ICIs. Moreover, aberrant
angiogenesis induces a hypoxic environment by recruiting VEGF, Treg cells and immune-suppressive
tumor associated macrophages (TAMs). On the other hand, factors such as gender and body mass
index seem to affect the response to ICIs, while the microbiome composition (and its alterations)
modulates both the response and the development of immune-related adverse events. Exploiting
these complex mechanisms is the next goal in immunotherapy. The most successful strategy to date
has been the combination of antiangiogenic drugs and ICIs, which prolonged the survival of patients
with non-small-cell lung cancer (NSCLC) and hepatocellular carcinoma (HCC), while results from
tryptophan pathway inhibition studies are inconclusive. New exciting strategies include targeting
the adenosine pathway, TAMs and the microbiota with fecal microbiome transplantation.
Keywords: immunotherapy; metabolism; ICI resistance; macrophages; antiangiogenic; adenosine
pathway; IDO inhibitors; PI3K/ALK pathway; microbiome
1. Introduction
The use of immune checkpoint inhibitors (ICIs)—monoclonal antibodies targeting programmed
death protein 1 (PD-1), programmed death protein 1 ligand (PD-L1) and CTLA-4—has yielded
impressive results in many settings and is currently a cornerstone in the treatment of metastatic
melanoma, non-small-cell lung carcinoma (NSCLC), renal cell carcinoma (RCC), urothelial carcinoma
and Hodgkin’s lymphoma (HL) [1–5]. However, the clinical benefit is not uniform in all cancer
types, ranging between an overall response rate (ORR) of 60–80% in relapsed/refractory Hodgkin
lymphoma (HL) to less than 20% in ovarian cancer, prostate cancer and hormone positive breast cancer
(BC), being the prospects for employing ICIs across a broader spectrum of tumors elusive so far [6,7].
Furthermore, clinical follow-up results have shown that a significant percentage of patients who are,
at first, responders eventually relapse with drug-resistant disease [8–10].
The mechanisms occurring in primary and secondary resistant tumors are complex and involve
both the tumor and the host itself (Figure 1) [10]. Among them, metabolic alterations that modify the
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tumor microenvironment (TME) and the physiological processes of the host play a central role in the
development of resistance to ICIs [10–14].
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Figure 1. Mechanisms of resistance to PD-1/PD-L1 inhibition. (A) Metabolic dysregulation at cellular 
level. (B) Altered tumor microenvironment. (C) Tumor cell adaptation. (D) Activation of alternative 
immune checkpoint. A = adenosine, AR = androgen receptor, CTLA-4 = cytotoxic T-lymphocyte 
antigen 4, CXCL2 = C-X-C Motif Chemokine Ligand 2, CXCR2 = C-X-C Motif Chemokine Receptor 2, 
CD39 = ecto-nucleoside triphosphate diphosphohydrolase 1, CD47 = integrin-associated protein, 
CD80/86 = B7 protein, DC = dendritic cell, GLS = glutaminase, HLA = human leucocyte antigen, IL-4 
= interleukin 4, IL-10 = interleukin 10, IDO = indoleamine 2,3-dioxygenase, IFN-γ = interferon gamma, 
JAK1 = Janus kinase 1, JAK2 = Janus kinase 2, LAG-3 = lymphocyte-activation gene 3, MHC = major 
histocompatibility complex, P = phosphate, PD-1 = protein cell death 1, PD-L1 = protein cell-death 
ligand 1, STAT-3 = signal transducer and activator of transcription 3, SIRPα = signal regulatory Protein 
alpha, TAM = tumor associated macrophages, TCR = T-cell receptor, TGF-β = transforming growth 
factor beta, Treg = regulatory T cells, VEGF = vascular endothelial growth factor. 
In this review, we describe key tumor and host metabolic pathways involved in resistance to 
ICIs. Moreover, we focus on possible strategies to overcome primary and acquired resistance and to 
improve the response to ICIs. 
We used the mesh keywords “immune-resistance”, “metabolism”, “immune checkpoints 
inhibitors” and “cancer”, manually selecting the most relevant papers in this field. We thus 
performed research on clinicaltrial.gov, selecting key ongoing clinical trials targeting immune 
metabolism 
2. Resistance to ICIs: Immune Metabolism Dysregulation at Cellular Level 
Multiple mechanisms such as the overexpression of immune checkpoint molecules, loss of 
nutrients through vasculature impairment and dysregulation of metabolic pathways were recently 
shown to affect T cell recruitment and metabolic activities in the TME [15–18]. These alterations, 
indeed, can put immune cells into a hypo-responsive state, resulting in T cell exhaustion and anergy, 
impairing the immune control of tumor growth and the response to ICIs [19–21]. Moreover, a great 
deal of attention has recently been given to the role of macrophages and myeloid-derived suppressor 
cells (MDSC) as mediators of tumor-associated immune suppression and ICI-resistance [22,23]. 
Figure 1. Mechanisms of resistance to PD-1/PD-L1 inhibition. (A) Metabolic dysregulation at cellular
level. (B) Altered tumor microenvironment. (C) Tumor cell adaptation. (D) Activation of alternative
immune checkpoint. A = adenosine, AR = androgen receptor, CTLA-4 = cytotoxic T-lymphocyte
antigen 4, CXCL2 = C-X-C Motif Chemokine and 2, CXCR2 = C-X-C Motif Chemokine Receptor
2, CD39 = ecto-nucleoside triphosphate diphosphohydrolase 1, CD47 = integrin-associated protein,
CD80/86 = B7 protein, DC = dendritic cell, GLS = glutaminase, HLA = human leucocyte antigen,
IL-4 = interleukin 4, IL-10 = interleukin 10, IDO = indoleamine 2,3-dioxygenase, IFN-γ = interferon
gamma, JAK1 = J nus kinase 1, JAK2 = Janus kinase 2, LAG-3 = lymphocyte-activation gene 3,
MHC = major histocompatibility complex, P = phosphate, PD-1 = protein cell death 1, D-L1 = protein
cell-death ligand 1, STAT-3 = signal transducer and activator of transcription 3, SIRPα= signal regulatory
Protein alpha, TAM = tumor associated macrophages, TCR = T-cell receptor, TGF-β = transforming
growth factor beta, Treg = regulatory T cells, VEGF = vascular endothelial growth factor.
In this review, w describe key tumor and host metabolic pathways involved in resistance to ICIs.
Moreover, we focus on possible strategies to overcome primary and acquired resistance and to improve
the response to ICIs.
We used the mesh keywords “immune-resistance”, “metabolism”, “immune checkpoints
inhibitors” and “cancer”, manually selecting the most relevant papers in this field. We thus performed
research on clinicaltrial.gov, selecting key ongoing clinical trials targeting immune metabolism
2. Resista ce to ICIs: Immune M tabolism Dysregulation at C llular Level
Multiple mechanis s su h as the overexpression of immune ch ckpo nt molecules, loss of
nutrients through vasculature impairment and dysregulation of metabolic pathways were recently
shown to affect T cell recruitment and metabolic activities in the TME [15–18]. These alterations,
indeed, can put immune cells into a hypo-responsive state, resulting in T cell exhaustion and anergy,
impairing the immune control of tumor growth and the response to ICIs [19–21]. Moreover, a great
deal of attention has recently been given to the role of macrophages and myeloid-derived suppressor
cells (MDSC) as mediators of tumor-associated immune suppression and ICI-resistance [22,23].
2.1. Inhibitors of the Adenosine Pathway
Adenosine, generated from adenosine-tri-phosphate (ATP) by the ectonucleotidases CD39+ and
CD73+, is a well-described anti-inflammatory modulator of the immune response in peripheral
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tissues [24]. In inflamed and damaged tissues (i.e., cancers), extracellular adenosine can increase
in concentration by up to 100 times and accumulate, inhibiting the effector functions of various
immune cell populations—including CD8+ T cells, natural killer (NK) cells, dendritic cells (DC) and
macrophages—but also enhance the proliferation and polarization of immunosuppressive cells, thereby
promoting the progression of neoplasms [25].
There are four G protein-coupled adenosine receptors (ARs): A1R, A2AR, A2BR and A3R [26].
Once activated, ARs induce the differentiation of monocytes to macrophages. Moreover, they stimulate
the immune tolerance by promoting activity of macrophages and affecting their production of IL-12
and TNFα [27,28]. Adenosine also influences neutrophils’ activity: it reduces their adherence,
transmigration and degranulation, finally causing an inhibition of Fc receptor-mediated phagocytosis
and superoxide production [29–31].
Moreover, it has been demonstrated that CD73+ tumor cells are resistant to PD-1 blockade and
that the simultaneous blockade of CD73+ and PD-1+ could augment intra-tumoral CD8+ infiltration
and enhance tumor control and survival in mice [32,33].
Several drugs such as those targeting CD39+ and CD73+ (that generate adenosine) and anti-AR
agents (that consume adenosine) have been proven efficacious in preclinical studies and mouse tumor
models [34].
Of note, the concurrent inhibition of CD39 and CD73 failed to potentiate the suppression of
adenosine production in cancer cell lines [35].
Novel antibodies and small molecules targeting this pathway are now under investigation in
early-phase clinical trials enrolling patients with advanced cancer and may be combined with standard
chemotherapy and checkpoint inhibitors to revert immune resistance [36,37] (Table 1).
Table 1. Selected ongoing clinical trials exploring adenosine pathway.
Molecular
Target Agents Phase Indications
Clinical Trial
Identifier Status
CD73 Oleclumab +Durvalumab II
Renal, pancreatic, head
and neck and NSCLC with
DNA Methylation
NCT04262375 Active notrecruiting


































I Solid tumors NCT04261075 Recruiting
Recently, results from a Phase 1 trial exploring the combination of oleclumab (anti-CD73) and
durvalumab were reported by Overman et al. [38]. Combination therapy showed encouraging clinical
activity in pancreatic cancer (pancr) and, potentially, in colorectal cancer (CRC). Partial Response
(PR) was observed for 1/21 CRC and 2/20 pancr patients; stable disease (SD) was observed in 2/21
CRC and 3/20 pancr patients, respectively. The most frequent toxicities in the expansion cohort were
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diarrhea (8.7%), pyrexia (8.7%), fatigue (6.5%), and alanine aminotransferase (ALT) (6.5%), aspartate
aminotransferase (AST) (6.5%), and ALP increases (6.5%) [38].
2.2. Inhibitors of Angiogenesis Pathways
The TME is a complex system composed of both blood and lymphatic vessels and filled by immune
cells (resident DCs, MDSCs, tumor-associated macrophages (TAMs) and resident and infiltrating T cells,
including regulatory T cells (Treg)) but also stromal cells and CAFs (cancer activated fibroblasts) [39,40].
The cancer vasculature is aberrant both structurally and functionally and thus favors an hypoxic
environment with a low pH and high interstitial pressure due to alternative lymphatic drainage,
which in turn cause an immune-tolerant setting [39,40]. In this context, Treg cells, TAMs and altered
endothelial cells (ECs) replicate, while there is a reduction in DC maturation. All these changes induce
altered antigen presentation and inhibit the migration of CD8+ T cells into the tumor core [41–43].
Furthermore, the abnormal TME lead TAMs to polarize from an anticancer M1-like phenotype towards
an immunosuppressive M2 phenotype
Importantly, there is an upregulation of the PD-1/PD-L1 pathway both in immune cells and tumor
cells, thus exhausting this mechanism. Lastly, from a biohumoral point of view, the vascular endothelial
growth factor (VEGF) both induces the growth of MDSCs and enhances their immune-modulatory
activity [44,45].
Thus, drugs that modify the TME might improve the effectiveness of immunotherapy.
Antiangiogenic agents can alleviate immunosuppression, enabling CD8+ T cells to access the tumor
tissue by relieving endothelial anergy and increasing adhesion molecule expression, thus augmenting
checkpoint blockade activity [46,47].
Several clinical trials evaluating the combination of anti-PD-L1, anti-PD-1 or anti-CTLA-4 agents
with anti-VEGF therapies (above all, bevacizumab) have been conducted in multiple tumor types and
in different settings.
Given the number of these studies, we report key trials with available results (Table 2).
Of note, the anti-PD-L1 agent atezolizumab plus bevacizumab in combination with carboplatin
and paclitaxel has already received FDA approval for the treatment of metastatic non-squamous
NSCLC with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK)
genomic tumor aberration based on the IMpower 150 results [48,49]. Regulatory approval is also
under evaluation for the treatment of patients with unresectable hepatocellular carcinoma (HCC) not
receiving prior systemic therapy, according to the IMbrave 150 study [50,51].





Tumor Type Phase Clinical TrialIdentifier Reference
Atezolizumab NSCLC III NCT02366143(IMpower 150) Socinski et al., Lancet Resp, 2019 [49]
Pembrolizumab NSCLC II NCT02039674(Keynote-021)
Gandhi et al., Lancet Oncol, 2016 [52]
Gandhi et al., J Thor Oncol, 2019 [5]
Atezolizumab Hepato-cellular carcinoma (HCC) III NCT03434379(IMbrave 150)
Cheng et al., ESMO, 2019 [50]
Finn et al., NEJM, 2020 [51]
Atezolizumab Renal cell carcinoma (RCC) III NCT02420821(IMmotion 151) Motzer et al., Lancet, 2019 [53]
Atezolizumab RCC II NCT01984242(IMmotion150) Powles et al., Nat Med, 2018 [54]
Atezolizumab Microsattelite-instable (MSI) mCRC Ib NCT01633970 Hochster et al., JCO, 2017 [55]
Ipilimumab Melanoma I NCT00790010 Hodi et al., CancerImm, 2014 [56]
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Additional trials evaluating anti-PD-L1 agents plus bevacizumab alone or as part of a larger regimen
are actually recruiting in multiple cancer settings including CRC (NCT03869190 and NCT04068610),
ovarian cancer (NCT03353831, NCT03806049, NCT03737643 and NCT03596281), HCC (NCT03847428
and NCT03778957) and BC (NCT03395899) and in patients with untreated melanoma brain metastases
(NCT03175432) or mucosal melanoma (NCT04091217).
2.3. Inhibitors of the Tryptophan–Kynurenine–Aryl Hydrocarbon Receptor Pathway
Tryptophan catabolism is involved in physiological immune suppression through the tryptophan–
kynurenine–aryl hydrocarbon receptor (Trp–Kyn–AhR) pathway, and it plays a role in acquired and
intrinsic resistance to immunotherapy [57]. Three enzymes are involved in this pathway, among
which indoleamine 2,3-dioxygenase (also called as IDO1) is the most studied, while another two
enzymes—tryptophan-2,3-Dioxygenase (TDO), regulated by tryptophan, cholesterols, and prostaglandin
E2, and IDO2, whose activity and regulation is uncertain—play a minor role in this pathway [58].
IDO1 is ubiquitously expressed, being mostly represented in the gut, lung and genital tracts [59].
It is expressed by macrophages and DCs, and its transcription is regulated, above all, by IFNγ [59].
IDO1’s immunosuppressive activities are both direct, through the depletion of tryptophan,
and indirect, with the production of metabolites like kynurenine [60]. Indeed, the depletion of this
essential amino acid leads to an accumulation of empty tryptophan-tRNA, with a stress response that
causes T cell anergy, while kynureninecan inhibits the activation of T cells, inducing IDO1 expression
in DC and the activation of Treg lymphocytes [60,61].
The physiological role of IDO1 is to induce acquired immune tolerance (i.e., towards fetal antigens
during pregnancy), while this enzyme seems not to be involved in the constitutive maintenance of
immune tolerance toward self-antigens [62,63].
IDO1 also plays an aberrant role in tumors. Its presence has been observed in several cancer cell
lines (endometrial, CRC and melanoma), and it shows a strong correlation with a worse outcome,
lower presence of tumor infiltrating lymphocytes (TILs) and high percentage of Treg cells [64–66].
Moreover, IDO1 expression in the peritumoral stroma strongly correlates with a low immune
response. High IDO1 in sentinel lymph nodes has demonstrated to be associated with a reduction
in TILs and worse prognosis in melanoma patients [67]. It exerts an inhibitory role and reduces the
response to both anti-CTLA-4 and anti-PD1/PDL1 therapy, while the inhibition of IDO1 expression
potentiates the response to both immunotherapy and chemotherapy [68,69]. Actually, IDO knockout
mice with melanoma have longer survival than wild-type ones when treated with immunotherapy,
while the combination of an IDO inhibitor with cytotoxic drugs like paclitaxel or with ICIs reduces
tumor growth in mice with melanoma and BC [68,69].
Based on these data, several IDO inhibitors have been developed. Among them, epacadostat
(INCB024360)—an orally available, reversible competitive IDO1 inhibitor—showed potent anti-IDO1
activity in vitro, resulting in T/NK cell proliferation and Treg lymphocyte suppression [70–72].
Results from a phase I trial, which haS enrolled 52 patients with advanced tumors, suggested
that epacadostat has manageable side effects and exerts an adequate IDO1 inhibitor activity,
with indirect pharmacodynamical data showing a significant reduction in plasma kynurenine levels [73].
The reported dose limiting toxicities (DLTs) were fatigue and pneumonitis; no objective responses were
recorded, with stable disease (SD) as the best response in 13.5% of patients [73].
Subsequently, early phase studies combining epacadostat with other treatments were more
promising. Data from the ECHO-202 and ECHO-204 Phase I/II studies showed a safe toxicity profile for
the combination of epacadostat with pembrolizumab and nivolumab, respectively [74,75]. The most
frequent adverse events (AEs) were skin rash and lipase elevation, with promising data regarding
activity [74,75]. It is noteworthy, indeed, that ORRs of 55% for the combination of pembrolizumab
and epacadostat and of 75% for the combination of nivolumab and epacadostat were achieved in the
melanoma cohort with interesting, although lower, ORRs in other tumor types like head and neck
(H&N) cancer, urothelial cancer and NSCLC [71,75,76].
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Due to these encouraging results, a Phase III trial (ECHO-301) was conducted. It recruited 706
ICI-naïve patients with unresectable Stage III or IV melanoma [77]. They were randomized to receive
epacadostat at 100 mg orally twice daily plus pembrolizumab at 200 mg every 3 weeks or a placebo
plus pembrolizumab for up to 24 months [77]. This study’s results were negative; indeed, with a
median follow up of 12.4 months (IQR, 10.3–14.5), there were no differences in progression free survival
(PFS) (HR, 1.00; 95% CI, 0.83–1.21; one-sided p = 0.52) or overall survival (OS) (median not reached in
either group; HR, 1.13, CI, 0.86–1.49; one-sided p = 0.81) [77]. The most recorded Grade 3 or worse
toxicity was a lipase increase, in less than 5% of patients in both arms [77].
Several doubts regarding the ECHO-301 trial remain. The most relevant ones are if the dose used
was sufficient to inhibit IDO1 activity in the TME (with pharmacodynamical data on IDO1 inhibition
from Phase I trials only giving an indirect suggestion of activity) and, above all, if targeting only IDO1
is sufficient to control tryptophan catabolism or if the use of a dual inhibitor may be more successful in
these patients [58].
The results of the ECHO-301 trial, however, were consistent with those reported in other Phase II
and III trials conducted in different settings. In NSCLC patients (KEYNOTE-715-06/ECHO-306-06),
the combination of epacadostat, pembrolizumab and platinum-based chemotherapy does not guarantee
a benefit in ORR. In RCC (KEYNOTE-679/ECHO-302), no difference in ORRs were observed
between pembrolizumab plus epacadostat compared to the standard of care—sunitinib or pazopanib.
In recurrent or metastatic H&N squamous cell carcinoma (KEYNOTE-669/ECHO-304), the combination
of epacadostat and pembrolizumab was not more powerful but was less toxic than the EXTREME
regimen [78].
Beyond epacadostat, new IDO inhibitors are under clinical development, such as navoximod
(NLG-919), an oral dual IDO1 and TDO inhibitor, and BMS-986205, an irreversible IDO1 inhibitor [70].
Navoximod showed an ORR of only 11% in combination with atezolizumab in heavily pretreated
patients, with a safe profile [79]. On the other hand, BMS-986205, in combination with nivolumab,
achieved an ORR of 34% in the advanced bladder cancer cohort of a Phase I/II trial (NCT02658890),
and a Phase III trial is ongoing in muscle-invasive bladder cancer patients [80].
Taken together, these results might suggest reconsidering the IDO inhibition strategy overall.
Indeed, off-target effects of IDO inhibition—such as the prolonged activation ofAhR,
the iper-activation of the mTOR pathway and the alteration of the gut microbiota—might be responsible
for the lack of efficacy of these compounds [58]. On the other hand, these off-target effects could be
exploited to find new powerful combinations and to implement the research on predictive biomarkers
to select the most suitable population [81].
See Table 3 for ongoing clinical trials targeting this pathway.
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Table 3. Selected ongoing clinical trials exploring the tryptophan–kynurenine–aryl (Trp–Kyn–AhR) pathway.
Molecular Target Agents Phase Indications Clinical TrialIdentifier Status


























II Head and neck (H&N)cancers NCT03823131 Recruiting
IDO-1 Nivolumab +MS986205 II H&N cancers NCT03854032 Recruiting
IDO-1 Nivolumab +MS986205 II
Endometrial carcinoma








III Muscle-invasivebladder cancer NCT03661320 Recruiting
2.4. The PI3K/AKT/mTOR Pathway
The PI3K/AKT/mTOR pathway is physiologically involved in multiple functions, among which
cell growth and survival, metabolism and motility are the most important [82]. Briefly, this pathway
is activated by growth factors via receptor-tyrosine kinases (RTK); these kinases phosphorylate
phosphatidylinositol-4,5-bisphosphate (PIP2) into phosphatidylinositol-3,4,5-trisphosphate (PIP3),
inducing a cascade that eventually causes the recruitment and activation of phosphoinositide 3-kinase
(PI3K), phosphoinositide-dependent kinase-1 (PDK1), mammalian target of rapamycin complex 2
(mTORC2) and AKT [82]. Then, AKT activates mTORC1, which induces cell proliferation and survival
and increases cell metabolism [82]. PI3Ks are divided in three classes, among which Class I is the best
characterized. It is further divided into Class IA PI3Ks (PI3Kα, PI3Kβ and PI3Kδ) and Class IB PI3Ks
(PI3Kγ) [83].
Beyond its role in normal cells, this pathway is also dysregulated in about 30% of cancers,
mediating tumor initiation, progression and drug resistance. Several mechanisms are involved,
including activating mutations of RTK, PI3K, AKT or RAS or inactivating mutations of regulatory
proteins like the phosphate and tensin homologue (PTEN) [84].
Recent studies have focused their attention on the role of the PI3K/AKT/mTOR pathway in the
immune response. Preclinical data suggest that an alteration of the PI3K/AKT/mTOR pathway might
promote an immunosuppressive response [85].
PTEN-mutant melanoma murine models showed a higher expression of immune suppressive
cytokines, a decreased infiltration of CD8+ T cells and a reduced T cell-mediated cytotoxicity,
while treatment with a PI3Kβ inhibitor enhanced the response to both PD-1 and CTLA4 inhibitors [86].
PIK3CA-mutated bladder cancer patient-derived xenografts (PDXs) have a non-T-cell-inflamed
phenotype, while the administration of BKM120, a pan PI3K inhibitor, induces immune activation and
the response to PD-1 inhibitors [87].
Other evidence highlights that PDL-1 expression in tumor cells is also related to this pathway.
Indeed, both PTEN-mutant triple negative breast cancer (TNBC) and CRC have higher expression of
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PDL-1. Moreover the use of a PI3K inhibitor or of rapamicin induces a reduction in PDL-1 expression
in tumor cells [88–90].
The PI3K pathway also regulates MDSC differentiation. High PI3Kδ expression is related to a
higher number of FOXP3+Treg cells, while the use of an inhibitor of this pathway reduces Treg cells
without affecting CD8+ TILs and reduces tumor growth [91–93].
Lastly, preclinical data suggest that the PI3K/AKT pathway is involved in the metabolic shift
(from glycolysis to oxidative phosphorylation) that converts effector CD8+ T cells to memory T cells [94]
and regulates the tumor associated macrophages’ (TAMs’) switch between immune stimulation and
immune suppression [95].
This pathway has already been targeted therapeutically on the basis of its pleiotropic role in
several malignancies. mTOR inhibitors, PI3K inhibitors (PI3Ki), dual PI3K–mTOR inhibitors and AKT
inhibitors are approved in different settings such as advanced RCC (temsirolimus and everolumus),
advanced ER+ BC (alpelisib and everolimus) and chronic lymphatic leukemia (CLL) (idelalisib) [84].
Nevertheless, its role in the immune response has not been exploited until recently.
New early phase studies with combinations of ICIs and PI3k/AKT/mTOR inhibitors aim at
enhancing the immune response based on the aforementioned strong preclinical rationale. Preliminary
data from a Phase I trial show that ipatasertib, an AKT inhibitor, added to atezolizumab and paclitaxel
or nab-paclitaxel as a first-line treatment in TNBC guarantees an ORR of 73% (95% CI, 53–88) regardless
of PD-L1 status or PIK3CA/AKT1/PTEN alteration status. Moreover, the toxicity profile was acceptable,
with Grade ≥3 AEs recorded in 54% of patients, the most frequent all-grade AEs being diarrhea
(88%; with a grade ≥3, 19%) and rash (69%; with a grade ≥3, 27%) [96]. A Phase III study is ongoing in
these patients (NCT04177108).
Other trials are actually combining drugs that target this pathway with immune checkpoint
inhibitors alone (NCT03131908) or in combinations with other compounds (NCT03772561).
Among them, a Phase I/II trial is exploring a PI3K inhibitor with nivolumab and ipilimumab
(NCT04317105) in PI3K/AKT-mutated solid tumors, while a combination of Nab-rapamycin and
nivolumab is under development in advanced sarcoma (NCT03190174) (Table 4).
Table 4. Selected ongoing clinical trials exploring the PI3K/AKT pathway.
Molecular




















I/II PI3K/AKT-mutated solid tumors NCT04317105 Not yetrecruiting
PIK3b+ PD-1 GSK2636771 +embrolizumab I/II PTEN-deficient melanoma NCT03131908 Recruiting





I/II Advanced sarcoma NCT03190174 Recruiting
2.5. Targeting Tumor-Associated Macrophages
Tumor-associated macrophages (TAMs) are fundamental components of the microenvironment
of solid tumors. TAMs express immune checkpoint modulators including PD-L1 and chemokines
such as CCL17, CCL22, CXCL10 and IL-8, which attract Tregs to tumor sites, downregulating
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the immune-response [97,98]. Although the main population of TAMs is immunosuppressive M2
macrophages, TAMs can be re-programmed into M1-type helper macrophages to enhance the antitumor
effects of checkpoint inhibitors [99].
The first and most widely used therapeutic macrophage-based strategy has been TAM depletion
from tumor sites via the inhibition of colony stimulating factor-1/colony stimulating factor-1 receptor
(CSF-1/CSF-1R) and CCL2/CCR2 inhibition [100,101]. Despite interesting pre-clinical results in mouse
models, this strategy has failed to show activity in clinical trials to date [102].
Other explored strategies are the inhibition of PI3Kγ, CCL5-CCR5 and CXCR2 but also the
use of antibodies binding the macrophage-derived protein MARCO [103]. Moreover, drugs that
antagonize the CD47-SIRPα pathway are under development; CD47 is a transmembrane protein both
on normal and cancer cells. Its signaling is based on an anti-phagocytic response, inducing resistance
to phagocytosis by macrophages. Magrolimab is a first-in-class CD47 inhibitor that has been tested in
a clinical trial, but several other agents are under study now [104–106]. Selected ongoing trials with
drugs targeting macrophage checkpoints are listed in Table 5.
Table 5. Selected ongoing clinical trials exploring macrophage checkpoint blockade.
Molecular
Target Agents Phase Indications
Clinical Trial
Identifier Status
CSF-1R SNDX-6532 +Durvalumab II Cholangiocarcinoma NCT04301778 Recruiting
CSF-1R Cabiralizumab +Nivolumab II
Peripheral T cell
lymphoma NCT03927105 Recruiting
CSF-1R DCC-3014 +Avelumab Ib High grade sarcomas NCT04242238 Recruiting
CXCR2 AZD5069 +Enzalutamide II
Metastatic castration
resistant prostate cancer NCT03177187 Recruiting
MDSCs SX-682 +Pembrolizumab I Melanoma NCT03161431 Recruiting
CCR5 Leronlimab (PRO 140) + carboplatin Ib/II TNBC NCT03838367 Recruiting
CD47 SGN-CD47M I Solid tumors NCT03957096 Recruiting
CD47 Magrolimab +chemotherapy I
B-cell Non-Hodgkin’s
lymphoma NCT02953509 Recruiting
3. Immune-Metabolism Dysregulation at Host Level
The metabolism of the host itself is physiologically involved in the immune response and can play
a role in both de novo and acquired resistance to ICIs [10]. Some characteristics, like body weight and
gender, seem to impact the immune response, but the data are still few and controversial [11,107]. On the
other hand, the composition of the microbiome affects the efficacy of ICIs and is also an intriguing target
for potentially building up and fostering the immune response in different malignancies [108,109].
3.1. Obesity Paradox
Excess body weight is a major public health problem worldwide. Indeed, an elevated body mass
index (BMI) has been associated with reduced cancer survival, with ten obesity-related cancers listed
by World Cancer Research Fund [110,111].
However, some recently published studies demonstrated that, among patients with a diagnosis of
cancer, an elevated BMI is unexpectedly associated with improved survival, in the so-called “obesity
paradox” [112–118]. The obesity paradox has been postulated in different metastatic and non-metastatic
settings such as in patients with RCC and CRC receiving surgery [112,114,117] and patients affected by
lymphoma who have underwent autologous hematopoietic cell transplantation [119]. Interestingly,
an analysis of a cohort of 423 metastatic melanoma patients suggested a positive association between
the benefit from ICIs and BMI, but it was burdened by several confounders [107]. Moreover, in a
retrospective analysis of 55 NSCLC patients treated with immunotherapy, a higher BMI was related to
a longer OS, while hypercholesterolemia was related to a longer PFS [120].
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A possible explanation for the obesity paradox might be the immune-suppressed phenotype
frequently observed in obese patients as a result of chronic inflammation, with a decrease in natural
killer T cells, CD8+T cells and M2 macrophages and an increase in PD-1 expression [121].
Moreover, the pharmacokinetics of ICIs are extremely different from those of classical cytotoxic
agents, as they are metabolized, above all, in the liver, and their metabolism might be compromised in
obese patients due to the altered metabolism of free fatty acids and the presence of pro-inflammatory
cytokines [107,121,122]. A plausible altered clearance, together with the diffuse use of flat doses in ICI
administration and the lack of data analyzing the pharmacokinetics in patients with high BMIs make
the relationship between BMI and the ICI response even more complex [107].
Lastly, some methodological considerations should be addressed. First, the time-point at which
the BMI was determined during these studies is important: before the diagnosis, peri-diagnosis or
post diagnosis (usually 12 months after the treatment’s start) [110,118]. Wu et al. showed a better
survival outcome for patients who were overweight post-treatment but not in patients with a high
pre-diagnosis BMI [123]. Age is another aspect to be considered as a potential bias factor. In fact,
both Brunner et al. and Navarro et al. observed that the obesity paradox was confirmed only in
younger patients and not in patients older than 60 years [115,124]. Another limitation of the use of BMI
is that it does not differentiate between lean mass and fat mass. In a study enrolling 175 patients with
breast, gynecological, lung, gastrointestinal and H&N carcinomas, the obesity paradox was confirmed
only using BMI and not when obesity was defined using other indices such as the fat-free mass index
or fat mass index [125].
3.2. Gender Effect
Sex chromosomes and hormones are involved in the regulation of both local and systemic
determinants of carcinogenesis, such as cancer-initiating cells, the composition of the TME,
cell metabolism and the immune system’s functions [126].
One of the most important differences between male and female bodies is related to the percentages
of lean and fat mass: lean, and metabolically active, mass is responsible for 80% of a man’s and 65% of
a woman’s body mass, although it is not a variable considered in the dosing of standard chemotherapy
or ICIs [127].
Differences in the physiological immune response can justify a distinct benefit from ICIs in
male and female populations. Several meta-analyses evaluated whether there were gender-related
differences in the ICI response [11,126,128–131].
Four of them suggested that anti-CTLA-4 treatment might guarantee a longer survival in men but
not in women [11,128,131,132].
However, the suggested absence of benefit from anti-CTLA-4 in female patients needs to be
interpreted really carefully. On the one hand, the early phase of the immune response is stronger in
women, both in terms of more efficient APCs and a wider population CD4 + T cells [133].
On the other hand, these results may be specific for some tumor types, not being confirmed in a
population of women with melanoma [126,131].
Moreover, these meta-analyses rely on published results and not on raw data, making it difficult
to control bias in the selection criteria and confounding factors like lifestyle or attitude and compliance
with treatment [134].
As demonstrated by Han et al. with a rigorous computational approach, there is an unexpected
divergent pattern in sex-associated differences across different cancer types (melanoma and lung
cancer) [135].
Lastly, a great deal of interest was raised in biomarkers of response. Some differences based on
gender have been highlighted in the neoantigen load, PD-L1 protein expression and tumor mutational
burden (TMB), as well as in other immune checkpoints (e.g., LAG3 and IDO1) and the distribution of
immune cell populations (active CD4/CD8 T cells, memory CD4/CD8 T cells and Treg cells) [135].
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These results, taken together, suggest prospective clinical trials stratified by gender in the
randomization process.
3.3. Microbiota
The intestinal microbiota has been estimated to contain more than 100 trillion bacteria [136].
The interactions between resident microbes and the immune system have been largely explored [137].
Zitvogel et al. hypothesized that the microbiota plays a role in antitumor immunosurveillance
through the cross-reactions between the microbiota and tumor antigens, the production of bacterial
metabolites that might have systemic modulatory effects and the stimulation of pattern-recognition
receptors (PRRs) [138].By activating PRRs, mostly expressed by innate immune effectors, microbes
can stimulate the production of cytokines and interferons, which can determine the tendency to
inflammatory and immunostimulatory or, on the other hand, to immunosuppressive reactions [138].
The composition of the intestinal microbiota in mouse models seems to affect the efficacy of
ICIs [109,139]. In particular, Sivan et al. showed that genetically identical mice derived from two
different mouse facilities and with differences in their commensal microbes showed a distinct tumor
growth and response to immunotherapy, while cohousing leveled those differences [109].
Several authors have also confirmed these hypotheses in human species, reporting that a particular
gut microbiota composition could affect the response to immunotherapy in different tumors such
as melanoma, NSCLC, RCC, and urothelial carcinoma [108,140,141]. Frankel et al. published the
first report on human gut microbiota metagenomic and metabolomic profiling in melanoma patients
treated with immunotherapy, showing that ICI responders were enriched for Bacteroidescaccae [142].
A wide-diversified microbiota seems to be more frequent in patients with a great benefit from the
treatment, with a direct correlation between a large diversification of the microbiota and a higher
number of T cell numbers in both the blood and TME [108,140,141].
An interesting field of discussion is how concomitant medications can modify the gut microbiota
and, eventually, the response to ICIs.
The associations between antibiotic (ATB) usage and the efficacy of immunotherapy was
investigated in different studies with contradictory results [139,143–145]. In the retrospective study
of Derosa et al., 121 patients with RCC and 239 patients with NSCLC were evaluated [144]. Patients
treated with recent ATB therapy (30 or 60 days before the administration of ICIs) were compared with
patients who did not receive ATBs, with the results highlighting a shorter PFS and OS for those patients
receiving an ATB in both the RCC and NSCLC groups [144].
Furthermore, the combination of ATBs and proton pump inhibitors (PPI) has also been associated
with gut dysbiosis, decreased bacterial richness, and the promotion of T-cell tolerance [146].
Chalabi et al. recently published an analysis including 1500 patients from randomized, controlled
trials and first reported a detrimental effect of PPI and ATBs on ICI efficacy in patients with advanced
NSCLC [146].
It seems that ATB treatment may reduce the efficacy of ICIs, undermining the wide array of
bacterial species, each one with a distinct metabolomic and metagenomic profile [108,140,141].
Similarly, PPI affect the gut microbiome; it is suggested that they directly increase stomach pH,
whose role is, physiologically, to prevent infections from food-derived and oral bacteria [147].
Lastly, the composition of the microbiota can also affect the resistance to immune-related adverse
events (IrAEs) [148–150]. A study demonstrated that the presence of bacteria belonging to the
Bacteroidetes phylum in the intestinal microbiota is correlated with resistance to the development of
ICI-induced colitis [148]. In a prospective study, a baseline gut microbiota enriched with Faecalibacterium
and other Firmicutes is associated with both a better clinical response to ipilimumab and a higher risk
of ipilimumab-induced colitis [149].
To date, the available studies have been too heterogeneous, above all because it has been very
difficult to use a standardized methodology in this field; therefore, further investigation regarding the
role of the gut microbiota in ICIs’ resistance (and response) mechanisms are needed.
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A promising therapeutic approach using the microbiota seems to be fecal microbiome
transplantation (FMT), basically, a transplant of the feces from immune-responder patients.
In preclinical models, FMT in germ-free mice led to improved tumor control and a higher response
to immunotherapy [108,140,141]. Phase I and II trials in melanoma patients are ongoing (NCT03353402
and NCT03341143) exploiting FMT to revert immune resistance. An ongoing early Phase 1 trial
(NCT03686202) explores another approach, alternative to fecal transplantation—microbial ecosystem
therapeutics (MET), a defined mixture of pure live cultures of intestinal bacterial isolates from a stool
sample of a healthy donor administered with ICIs.
Other strategies such as oral supplementation with specific bacteria or antibiotic therapy might
modify the intestinal microbiota in order to enhance the effect of anticancer therapies and, hopefully,
in the future, to overcome resistance to ICIs [109,140].
4. Conclusions and Future Perspectives
The therapeutic algorithm has been massively changed by the introduction of ICIs for several
malignancies (from metastatic melanoma and advanced NSCLC to RCC, urothelial cancers and
squamous cell cancer of the H&N, and from hematologic cancers, such as classic Hodgkin’s lymphoma,
to rare tumors such as Merkel cell carcinoma) with, eventually, a broad-range approval for solid tumors
with microsatellite instability (MSI-H) and mismatch repair deficiency.
However, in this evolving field, primary and secondary resistance are an emerging issue [10].
Understanding de novo resistance may allow the discovery of predictive biomarkers of response
for increasing response rates in tumors that are theoretically “cold” (i.e., intrinsically resistant),
while tackling acquired resistance could prolong clinical benefit in patients who are initially responders
but then progress [10].
As described above, different metabolic pathways are involved, and most of them are
interdependent. Alterations of the TME, as well as mutations of cancer-related pathways, interact with
host factors such gender, BMI and, above all, variations in the microbiota, modifying the immune
response and, eventually, the benefit from ICIs [151,152]. These metabolic alterations are interesting
targets to overcome immune resistance, but although some of them have yet achieved regulatory
approval for modifying therapeutic algorithms, for others, the results are frankly disappointing or at
least controversial [49,51,77].
Several points need to be taken into account when designing new clinical trials and treating
patients with ICIs.
• Are there any predictive factors that should be taken into account for tailoring immunotherapy?
1. PD-L1 expression, microsatellite instability and the tumor mutational burden have already
been demonstrated to be useful biomarkers in specific settings; however, their sensitivity is
limited, and their effectiveness has been confirmed only in specific types of tumor [153].
2. Other predictive factors such as the genomic signatures and metabolic profiles associated
with ICI resistance are under preclinical and clinical evaluation, and some of them have
shown encouraging results [154]. The presence of mutations of Janus kinase 2 (JAK2),
beta2-microglobulin and serine/threonine kinase 11 (STK11) are some of the alterations that
have recently emerged as potential predictors of low responsiveness to ICIs [155–157].
3. Heterozygosity in the HLA class I genotype, a characteristic that facilitates the presentation
of a broader set of tumor antigens to T cells, is another possible response biomarker that has
been demonstrated to confer a higher responsivity to ICIs in cancer patients [158,159].
4. A dynamic research area aims at finding predictors of response, specifically for the
combination of antiangiogenics and ICIs. In patients with HCC treated with the combination
of bevacizumab and atezolizumab, there was a correlation between the expression of a
signature of pre-existing immunity, including PD-L1 (HR = 0.42) and T effector markers
(HR = 0.46), and a longer PFS while Notch pathway activation correlated with a worse clinical
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outcome [160]. Interestingly, higher levels of VEGF receptor 2 (HR = 0.36), Tregs (HR = 0.35),
myeloid inflammation (HR = 0.43) and triggering receptor expressed on myeloid cells 1
(TREM1)/MDSC signatures (HR = 0.43) were predictive of a longer PFS in patients treated
with atezolizumab and bevacizumab than in those who had received the ICI alone, suggesting
a possible role for these markers [160].
5. Among host factors, the gut microbiome composition is another potential predictor of
response. This is particularly interesting because the determination of the gut microbiome
does not require invasive procedures such as tumor biopsies [108,140].
• Considering host factor relevance, how should we modify both clinical trial designs and, eventually,
everyday practice?
1. Prospective clinical trials should consider a gender-based randomization approach. This may
significantly contribute to a deeper comprehension of the role of gender in the antitumor
activity of ICIs and help in the identification of predictors of response/resistance and toxicities
to ICIs, differently expressed in men and women.
2. Baseline BMI, not only performance status (PS), should be considered as a stratification factor
in future ICI trials.
3. The effect of antibiotics and proton pump inhibitors on the response to ICI therapy warrants
further investigation. Physicians should carefully evaluate the need for co-medications such
as antibiotics or proton pump inhibitors during immunotherapy.
In conclusion, metabolic pathways play a crucial, although not fully understood, role in both
intrinsic and acquired resistance to ICIs.
The reformulation of prospective clinical trials, taking into account host factors, and the
identification of both new predictive factors and new compounds tackling immune metabolism
might be the successful tools for comprehending and overcoming resistance in the immunotherapy era.
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